

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality and health inequalities assessment (EHIA)

Ectopic pregnancy and miscarriage (update)

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

The use of anti-D prophylaxis in pregnant people with a threatened miscarriage, miscarriage or ectopic pregnancy in the first trimester.

STAGE 4. Development of guideline or topic area for update
(to be completed by the developer before consultation on the draft guideline or update)

Ectopic pregnancy and miscarriage (update)

Date of completion: 11th December 2025

Focus of guideline or update: anti-D immunoglobulin prophylaxis

4.1 From the evidence syntheses and the committee's considerations thereof, what were the main equality and health inequalities issues identified? Were any **further** potential issues identified (in addition to those identified during the scoping process) or any gaps in the evidence for any particular group?

No evidence was identified concerning the main equality and health inequalities considered.

The committee discussed that anti-D immunoglobulin is a blood product, and as such may not be accepted by some people.

The committee also discussed that some geographical location and proximity of services could lead to barriers to people accessing anti-D prophylaxis, including cost of attending appointments and caring responsibilities.

The committee's consideration regarding this is detailed in the evidence review for anti-D immunoglobulin prophylaxis.

4.2 How have the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the guideline or update and any draft recommendations?

The committee's discussions of equality and health inequalities issues are in recommendation 1.7.4 and accompanying rationale. The recommendation outlines that the use of anti-D immunoglobulin should be discussed with the person, and that the discussion should include that it is a protein obtained from blood plasma and it does not contain blood cells.

4.3 Could any draft recommendations potentially increase inequalities?

None of the draft recommendations are considered to potentially increase inequalities.

4.4 How has the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the development of any research recommendations?

No research recommendations were made.

4.5 Based on the equality and health inequalities issues identified in 2.2, 3.2 and 4.1, do you have representation from relevant stakeholder groups for the guideline or update consultation process, including groups who are known to be affected by these issues? If not, what plans are in place to ensure relevant stakeholders are represented and included?

Yes. The guideline development team, advisory committee and people and communities team have identified all relevant stakeholder groups affected by these issues.

4.6 What questions will you ask at the stakeholder consultation about the impact of the guideline or update on equality and health inequalities?

We will ask stakeholders whether the guideline update is anticipated to increase any existing equalities or health inequalities issues.

Completed by developer: Sara Buckner

Date: 11th December 2025

Approved by committee chair: Sarah Fishburn

Date: 16/01/26

Approved by NICE quality assurance lead: Kate Kelley

Date: 12/01/26